AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

The trial will explore the ALS biomarkers, including the change from baseline in levels of neurofilament light chain.

The two researchers quickly homed in on a calpain known as calpain-5. They found that this enzyme undergoes rapid activation ...

The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.